MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY for MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report | Jan 21, 2014 | $280,000 | Replaced |
| 4th Quarter - Termination Amendment (this page) | Apr 8, 2014 | $280,000 | Yes |
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Pharmaceutical track and trace legislation or as packaged with/tied to pharmaceutical compounding legislation: HR. 1919 - Safeguarding America's Pharmaceutical Act of 2013, HR 3204 - Drug Quality and Security Act, HR 2186 VALID Compounding Act, and S. 959 Pharmaceutical Compounding Quality and Accountability Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| AARTI SHAH | — |
Health Issues HCR
Implementation of the new health care reform law - PL 111-148, specifically with regard to those provisions impacting Medicare/Medicaid prescription drug coverage, the essential benefit pkg., and other matters.
| Lobbyist | Covered position, as disclosed |
|---|---|
| AARTI SHAH | — |
Medicare/Medicaid MMM
S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014 H. Con. Res. 25 -- Establishing the budget for the U.S. Government for FY 2014 and setting forth appropriate budgetary levels for FY 2015 through 2033. H. J. Res. 59 -- Continuing Appropriations Resolutions, 2014 In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| AARTI SHAH | — |
Budget/Appropriations BUD
S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014 H. Con. Res. 25 -- Establishing the budget for the U.S. Government for FY 2014 and setting forth appropriate budgetary levels for FY 2015 through 2033. H. J. Res. 59 -- Continuing Appropriations Resolutions, 2014 In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| AARTI SHAH | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.